Who Needs Closer Monitoring for Tysabri-Related PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Understanding Tysabri and PML in the Context of General Health Science

If you or a loved one is taking Tysabri, you may be concerned about the rare but serious risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established that certain patient factors, such as JC virus antibody status and treatment duration, significantly influence risk. This guide covers who may need closer monitoring and what the science says about long-term outlook.

Bridging Clinical Knowledge to Legal Considerations

Shifting from this general clinical perspective to a more specific occupational exposure concern, it becomes relevant to consider the legal and regulatory frameworks that govern accountability for such risks. In the context of mass production and distribution of pharmaceutical agents, the question of liability arises when patients experience harm that may have been foreseeable or inadequately communicated. For individuals in New York who have been prescribed Tysabri and subsequently developed PML, the statute of limitations imposes a critical temporal boundary on their ability to seek legal recourse. This transition from a purely health-science understanding to a legal-occupational lens underscores the need for affected parties to be aware of time-sensitive filing requirements, thereby bridging clinical knowledge with actionable legal considerations.

Medical Evidence: Tysabri and PML Risk

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients have developed the infection even without other immunosuppressive conditions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML, and to withhold Tysabri dosing immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in this program, read the Medication Guide, understand the risks associated with Tysabri, and complete and sign the Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can be variable, but common symptoms include progressive neurological deficits such as weakness, gait disturbance, memory impairment, cognitive disorder, and balance disorder. FDA adverse-event reports for Tysabri frequently list fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, balance disorder, hypoesthesia, pain in extremity, muscular weakness, mobility decreased, stress, cognitive disorder, and depression (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms overlap with multiple sclerosis itself, any new or worsening neurological symptoms in a Tysabri-treated patient should raise suspicion for PML.

Mechanistic Pathway and Prognosis

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrin on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in multiple sclerosis but also impairs immune surveillance in the brain, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. For patients who develop PML after Tysabri treatment, the prognosis is poor. The boxed warning states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Treatment options are limited and primarily involve supportive care and restoration of immune function, often through plasma exchange to accelerate Tysabri clearance.

Legal Context: Statute of Limitations in New York

From a legal perspective, patients in New York who have developed PML after Tysabri treatment may have claims related to inadequate warnings about the risk of PML. The adequacy of warnings is a central issue because the boxed warning and TOUCH program were implemented after PML cases were reported, and questions remain about whether earlier or more prominent warnings could have prevented harm. The timeline between exposure and documented harm is critical: PML risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who received Tysabri for extended periods without adequate monitoring or risk stratification may have stronger claims. Attorney-related considerations for affected patients include the statute of limitations for product liability claims in New York. In New York, the statute of limitations for personal injury claims based on defective products is generally three years from the date of injury. However, the date of injury in PML cases can be difficult to determine because symptoms may develop gradually. The statute of limitations may begin to run when the patient knew or should have known that the injury was caused by Tysabri. Patients who were not adequately warned about PML risk may argue that the statute should be tolled until they discovered or reasonably should have discovered the connection between Tysabri and their PML. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to evaluate the specific facts of their case, including the duration of Tysabri treatment, presence of anti-JCV antibodies, prior immunosuppressant use, and the timing of PML diagnosis. The attorney can also assess whether the warnings provided to the patient and healthcare providers were adequate under New York law.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in New York?

In New York, the statute of limitations for personal injury claims based on defective products is generally three years from the date of injury. However, for PML cases, the date of injury can be difficult to determine because symptoms may develop gradually. The statute may begin to run when the patient knew or should have known that the injury was caused by Tysabri. Patients who were not adequately warned about PML risk may argue that the statute should be tolled until they discovered the connection. It is crucial to consult with an attorney experienced in pharmaceutical litigation to evaluate the specific facts of your case.

What are the risk factors for developing PML while on Tysabri?

Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. The boxed warning emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.